Namenda
E494105
Namenda is a prescription medication used to treat moderate to severe Alzheimer's disease by regulating the activity of glutamate in the brain.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Namenda canonical | 1 |
| Namenda XR | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T5114927 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Namenda Context triple: [Memantine, isMarketedUnderBrandName, Namenda]
-
A.
Donepezil
Donepezil is a cholinesterase inhibitor medication primarily used to treat cognitive symptoms of Alzheimer's disease.
-
B.
Toclafane
The Toclafane are a race of deadly, cybernetic spheres revealed to be the future remnants of humanity in the Doctor Who universe, serving as instruments of mass destruction under the Master.
-
C.
rivastigmine
Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
-
D.
riluzole
Riluzole is a neuroprotective medication that modestly prolongs survival and slows disease progression in people with amyotrophic lateral sclerosis (ALS).
-
E.
amantadine
Amantadine is an antiviral and antiparkinsonian medication used to help manage motor symptoms such as tremor and rigidity in people with Parkinson’s disease.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Namenda Target entity description: Namenda is a prescription medication used to treat moderate to severe Alzheimer's disease by regulating the activity of glutamate in the brain.
-
A.
Donepezil
Donepezil is a cholinesterase inhibitor medication primarily used to treat cognitive symptoms of Alzheimer's disease.
-
B.
Toclafane
The Toclafane are a race of deadly, cybernetic spheres revealed to be the future remnants of humanity in the Doctor Who universe, serving as instruments of mass destruction under the Master.
-
C.
rivastigmine
Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
-
D.
riluzole
Riluzole is a neuroprotective medication that modestly prolongs survival and slows disease progression in people with amyotrophic lateral sclerosis (ALS).
-
E.
amantadine
Amantadine is an antiviral and antiparkinsonian medication used to help manage motor symptoms such as tremor and rigidity in people with Parkinson’s disease.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
brand name medication
ⓘ
pharmaceutical drug ⓘ |
| affects | N-methyl-D-aspartate receptors ⓘ |
| approvalBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| availableAs |
oral solution
ⓘ
oral tablet ⓘ |
| blackBoxWarning | false ⓘ |
| brandOwnerRegion |
United States
ⓘ
linked to:
United States of America
|
| canBeAdministeredWithFood | true ⓘ |
| chemicalSubClass | adamantane derivative ⓘ |
| commonSideEffect |
confusion
ⓘ
constipation ⓘ dizziness ⓘ headache ⓘ hypertension ⓘ |
| contraindication | known hypersensitivity to memantine ⓘ |
| developedBy |
Allergan
ⓘ
Forest Laboratories ⓘ |
| dosageForm | immediate-release ⓘ |
| eliminationRoute | renal ⓘ |
| FDAApprovalYear | 2003 ⓘ |
| halfLife | about 60–80 hours ⓘ |
| hasActiveIngredient | memantine hydrochloride ⓘ |
| hasATCCode | N06DX01 ⓘ |
| hasExtendedReleaseBrand |
Namenda XR
ⓘ
linked to:
Namenda
|
| hasGenericName | memantine ⓘ |
| indication |
moderate Alzheimer's disease
ⓘ
severe Alzheimer's disease ⓘ |
| isNotDiseaseModifying | true ⓘ |
| legalStatusEU | prescription only ⓘ |
| legalStatusUS | Rx-only ⓘ |
| mayBeUsedWith | cholinesterase inhibitors ⓘ |
| metabolism | minimal hepatic metabolism ⓘ |
| pharmacologicalClass | NMDA receptor antagonist ⓘ |
| pregnancyCategoryUS | Category B ⓘ |
| prescriptionStatus | prescription only ⓘ |
| regulates |
excitatory neurotransmission
ⓘ
glutamate activity in the brain ⓘ |
| requiresCautionIn | severe renal impairment ⓘ |
| routeOfAdministration | oral ⓘ |
| symptomaticTreatment | true ⓘ |
| targetPopulation | patients with moderate to severe Alzheimer's dementia ⓘ |
| therapeuticClass | anti-dementia drug ⓘ |
| treats | Alzheimer's disease ⓘ |
| usedFor |
cognitive symptoms of Alzheimer's disease
ⓘ
functional symptoms of Alzheimer's disease ⓘ |
| usedIn | adult patients ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Namenda Description of subject: Namenda is a prescription medication used to treat moderate to severe Alzheimer's disease by regulating the activity of glutamate in the brain.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject linked to:
memantine
linked to: Namenda